Clinical Trial

Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if FRF-001 is a safe, tolerable, and efficacious treatment for children and adults with FOXG1 syndrome.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-07-25
notable Primary completion pushed: 2029-03 -> 2029-07 2026-07-25
minor Completion pushed: 2029-07 -> 2029-12 2026-07-25
Trial Details
NCT Number NCT07293546
Lead Sponsor FOXG1 Research Foundation
Conditions FOXG1 Syndrome
Enrollment 12 participants
Start Date 2026-07-20
Primary Completion 2029-07 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-24